Advanced in Graft Versus Host Disease (GvHD)

Dr. Pritesh R. Patel

Hematology | Oncology
Chicago, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Graft Versus Host Disease (GvHD)
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pritesh Patel is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Graft Versus Host Disease (GvHD).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Enrollment Status: Recruiting
Publish Date: August 20, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide
Study Phase: Phase 3
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
Enrollment Status: Recruiting
Publish Date: December 13, 2024
Intervention Type: Device, Drug, Other
Study Drugs: Fludarabine, Cyclophosphamide, Tacrolimus
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 13, 2024
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Melphalan, Filgrastim (G-CSF)
Study Phase: Phase 1
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve
Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve
Enrollment Status: Completed
Publish Date: September 23, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

70 Total Publications

Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.
Journal: Haematologica
Published: February 04, 2025
Similar Doctors
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Sunita R. Nathan
Hematology Oncology | Hematology | Oncology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Sunita R. Nathan
Hematology Oncology | Hematology | Oncology

Rush University Medical Group

1700 W Van Buren St, 
Chicago, IL 
 (1.0 miles away)
312-563-2875
Languages Spoken:
English, Hindi, Malayalam, Swedish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunita Nathan is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Nathan is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Graft. Dr. Nathan is currently accepting new patients in some locations.

Damiano Rondelli
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Damiano Rondelli
Hematology Oncology | Hematology | Oncology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Damiano Rondelli
Hematology Oncology | Hematology | Oncology

The Board Of Trustees Of The University Of Illinois

1855 W Taylor St, 
Chicago, IL 
 (1.1 miles away)
312-996-6590
Languages Spoken:
English, Italian
See accepted insurances

Damiano Rondelli is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Rondelli is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Polycythemia Vera, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Graft Versus Host Disease (GvHD)
Dr. Celalettin Ustun
Hematology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Celalettin Ustun
Hematology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (1.1 miles away)
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Celalettin Ustun is a Hematologist in Chicago, Illinois. Dr. Ustun is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ustun is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile